Angelini Pharma of Italy has agreed to spend up to $960 million to acquire a two-year old Swiss company with rights to an antiepileptic drug for the treatment of partial-onset seizures. The target company, Arvelle Therapeutics GmbH, was launched in 2019 with start-up capital of $207.5 in order to bring the antiepileptic, cenobamate, to the European market.
